Fundraising Fox
Obulytix
Ghent, BE · Founded 2023 · 18 employees on LinkedIn · 2 known investors
Find your way into Obulytix
Sign up to see every warm intro you have to Obulytix
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Obulytix team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Obulytix develops Precision Lysin Therapeutics, a novel class of engineered biologics designed to target multidrug-resistant Gram-negative bacteria for severe bloodstream and lung infections. The company was founded as a spin-off from Ghent University and KU Leuven to address antimicrobial resistance in healthcare.
Founders & leadership
Obulytix was founded in 2023 by Yves Briers.
Investors · 2
Frequently asked questions
- What does Obulytix do?
- Obulytix develops Precision Lysin Therapeutics, a novel class of engineered biologics designed to target multidrug-resistant Gram-negative bacteria for severe bloodstream and lung infections. The company was founded as a spin-off from Ghent University and KU Leuven to address antimicrobial resistance in healthcare.
- Who founded Obulytix?
- Obulytix was founded by Yves Briers in 2023.
- Who are Obulytix's investors?
- Obulytix's investors include Qbic Fund, Boehringer Ingelheim Venture Fund.
- Where is Obulytix headquartered?
- Obulytix is headquartered in Ghent, BE.